Breast Cancer Flashcards

1
Q

Outline the normal anatomy of the breast.

A
  • Breast is a sebaceous gland.
  • Made of glandular and fatty tissue.
  • 4 quadrants:
    Upper outer quadrant (greatest bulk of mammary tissue). Benign and malignant tumours most common here.
  • Upper border is in 2nd IC space just below the clavicle.
  • Lower border is at 6th IC space but clearly breast tissue can lie below this posterior attachment.
  • Medial: inner sternum.
  • Outer: anterior axillary line.
  • Axillary tail (include in breast examination)
  • Breast tissue changes in month due to menstruation and with pregnancy.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology: 1 in how many women are diagnosed with breast cancer?

A

1 in 9

1,000 new diagnoses a year in NI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Discuss the risk factors for developing breast cancer.

A
  • Increasing age
  • Environmental factors > genetic
  • Early first menarche (prolongs oestrogen exposure)
  • Late menopause (prolongs oestrogen exposure)
  • Age at first pregnancy (prolongs oestrogen exposure)
  • Obesity (aromatase in adipocytes –> increases oestrogen exposure)
  • Alcohol
  • Diet
  • Previous breast disease - CIS, atypical hyperplasia
  • Exogenous oestrogen: HRT, oral contraceptives
  • Genetics (BRCA-1, BRCA-2)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does breast cancer normally present?

A

Typically: painless breast lump found on asymptomatic screening.

  • Lump (most often)
  • Through screening (mammography every 3 years 50-70 years)

Less often:

  • Nipple discharge
  • Nipple retraction
  • Skin changes - rash, scaling, puckering
  • RARELY, pain
  • Family history - genetic component
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Outline breast clinic assessment.

A

Triple assessment (examination/imaging/biopsy):

+ History

  • Examination
  • Mammography/USS
  • MRI (if required)
  • FNA/core biopsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which tumour marker may be used to monitor response of breast cancer to treatment or to surveil for recurrence?

A
  • CA 15-3.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the classical characteristics of a palpable breast lump (cancer)?

A
  • Single lesion
  • Hard
  • Immobile
  • Irregular border
  • Skin dimpling
  • Skin > 2cm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Outline important characteristics of familial breast cancer (genetic).

A
  • 5% of total
  • Younger age of onset
  • Often bilateral
  • Autosomal dominant (maternal or paternal)
  • BRCA-1/BRCA-2 (tumour suppressor gene) - risk of ovarian cancer as well
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Outline NICE’s Suspected Cancer Referrals Pathway for breast cancer.

A
  1. Refer via the “Suspected Cancer Pathway”
    – age >30 + unexplained breast lump +/- pain
    – age >50 + unilateral nipple symptom
  2. Consider referring via the “Suspected Cancer Pathway”
    – skin changes that suggest breast cancer
    – age >30 + axilla lump
  3. Consider a routine surgery referral
    – age <30 + unexplained lump +/- pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List the differential diagnoses of a breast lump.

A

Most commonly:

  1. Fibroadenoma
  2. Fibrocystic change
  3. Intraductal papilloma
  4. Fat necrosis
  5. Breast abscess
  6. Invasive breast cancer
  7. Ductal carcinoma in-situ (DCIS)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe how the diagnosis of breast cancer is made (briefly).

A
  1. Clinical assessment (history + examination of both breasts)
  2. Imaging assessment (mammogram +/- USS)
  3. Tissue acquisition (FNA vs. core biopsy –> ductal vs. lobular)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Recall the TNM staging of breast cancer (give overview)

A
TNM covers pattern of spread 
T = local spread 
Size of largest (if multiple)
Local extension (skin or chest wall)
N = lymphatic spread 
Number of positive axillary nodes
M = haematogenous spread 
Bone, lung, liver, brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Recall the TNM staging of breast cancer (give specifics)

A
pT Stage
T1 < 2cm
T2 2-5 cm
T3 ≥ 5 cm
T4a chest wall
T4b skin 
T4c both
T4d inflammatory
pN Stage
NX not assessable
N0 no nodes
N1 1–3 nodes
N2 4–9 nodes
N3 ≥10 nodes

M Stage
M0 no metastases
M1 metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Discuss tumour-related prognostic biomarkers.

A
• De novo metastatic disease
• Nodal status
• Primary tumour size & grade
• T4 disease
• Lymphovascular invasion
• Receptor status:
– ER & PR: positive is good
– HER2: positive is poor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the surgical aim in the primary management of breast cancer?

A

Surgical Aim:
– Remove tumour: local control & possible cure
– obtain prognostic information (staging/node assessment)
- Restore anatomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Outline the types of surgical intervention.

A

Types of Surgery

a. wide local excision
b. mastectomy +/- reconstruction

17
Q

Outline axillary surgery in breast cancer management.

A

Axillary surgery:

Sentinel Node Biopsy (SNB)
– radioactive colloid & blue dye to peri-areolar area
– sentinel node located (Geiger counter & visualisation)
– ANC avoided if ≤1 node involved

• Axillary Clearance (ANC)
– >1 node positive on SNB
– N1–3 on examination/imaging 
– most patients have shoulder pain/stiffness
– 15% get lymphoedema
18
Q

Discuss the rational selection of adjuvant radiotherapy approaches.

A
  • Whole breast radiotherapy = post-WLE. Reduces local relapse.
  • Additional dose ‘boost’ to tumour bed = reserved for age <50, grade III, close margins, or “triple negative”
  • Chest-wall radiotherapy = post-mastectomy for ≥T3 or ≥N2
  • Ipsilateral supraclavicular fossa radiotherapy = ≥N2 disease
19
Q

What is the rationale behind adjuvant systemic chemotherapy?

A
  • Surgery often not ‘curative’
  • Cancer may have spread prior to this intervention
  • Micro-metastases a source of future relapse
  • If these are eliminated, the patient has the potential for a cure
20
Q

Discuss adjuvant hormonal therapy in breast cancer.

A

• 2/3 breast cancers are ER or PR positive
• Cells from these tumours are usually oestrogen–dependent
• Tamoxifen blocks the oestrogen receptors
• Aromatase inhibitors block oestrogen production in fat
– oestrogens arise from peripheral tissues due to the aromatase enzyme
– ovarian pathway available for oestrogen production pre-menopause
– hence AIs are effective in post-menopausal women only

21
Q

What hormonal therapy regime is preferred in pre-menopausal women?

A

Tamoxifen 20 mg daily for 5-10 years

22
Q

What hormonal therapy regime is preferred in post-menopausal women?

A

Tamoxifen 20 mg daily for 2 years then switch to aromatase inhibitors for 3-8 years OR aromatase inhibitors for 5-10 years (anastrozole/letrozole)

23
Q

Outline some adverse effects of tamoxifen treatment.

A
  • Menopausal symptoms
  • VTE
  • Low-grade uterine cancers
24
Q

Outline some adverse effects of aromatase inhibitor treatment.

A
  • Menopausal symptoms
  • Osteoporosis (MCQs often have a stem where a post-menopausal woman falls and fractures her femur post-cancer treatment)
  • Arthralgia
25
What is an important consideration when prescribing hormonal therapy?
- Don’t Forget Bone Protection! - Adcal D3 ± Bisphosphonate - DEXA Scan at Baseline + 2 Years
26
Discuss the rational selection of adjuvant chemotherapy approaches.
``` • FEC-100 – fluorouracil, epirubicin, cyclophosphamide – FEC x 6 cycles • FEC-D – FEC x 3 cycles, – docetaxel x 3 cycles (aka 3rd generation chemo) – more effective than FEC-100 – more toxic than FEC-100 ``` Important for MCQs: • Node-positive patients FEC-D • Node-negative patients FEC
27
What is HER2?
HER2 is a transmembrane EGFR receptor over-expressed in 20% of breast cancers
28
What does HER2 positivity mean for survival outcomes in breast cancer?
Median survival halved if HER2 positive.
29
Which targeted therapy is administer in HER2 positive breast cancers?
- Trastuzumab (Herceptin) - Humanised monoclonal antibody - Improves survival outcomes
30
Where does breast cancer typically metastasise?
- Bone - Brain - Liver - Lungs